Professor of Medicine; The Edward Fox Chair in Medicine
Massachusetts General Hospital , Harvard Medical School
Concord, MA, United States
Dr. Stone is a Professor of Medicine at Harvard Medical School and the Edward A. Fox Chair of Medicine at the Massachusetts General Hospital. He is the Founder and Executive Chairman for the IgG4ward! Foundation.
CARE: Retroperitoneal Fibrosis
Saturday, November 16, 2024
1:00 PM – 2:00 PM Eastern Time
Disclosure(s): Abvie: Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Argenx: Consultant (Ongoing); Aztrazeneca: Consultant (Terminated, December 31, 2022); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Celgene: Consultant (Terminated, December 31, 2022); Chemocentryx: Consultant (Terminated, December 31, 2022); Chugai: Consultant (Terminated, December 31, 2022); GSK: Consultant (Terminated, December 31, 2022); Horizon Therapeutics: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); InflaRx: Consultant (Terminated, December 31, 2022); IQVIA: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Kyverna: Consultant (Terminated, December 31, 2022); Mirabio: Consultant (Terminated, December 31, 2022); NIH: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); PPD: Consultant (Ongoing); Prometheus: Consultant (Ongoing); Q32: Consultant (Ongoing); Regeneron: Consultant (Terminated, December 31, 2022); Roche-Genentech: Consultant (Ongoing); Roivant: Consultant (Terminated, December 31, 2022); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); Spruce Biosciences: Consultant (Terminated, December 31, 2022); Star Therapeutics: Consultant (Ongoing); Steritas: Chair, Scientific Advisory Board (no fiduciary responsibilities) (Ongoing); ZenasBio: Consultant (Ongoing)
Recognize the Evolving Role of Steroids in Management of ANCA-Vasculitis
Sunday, November 17, 2024
10:30 AM – 10:50 AM Eastern Time
Disclosure(s): Abvie: Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Argenx: Consultant (Ongoing); Aztrazeneca: Consultant (Terminated, December 31, 2022); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Celgene: Consultant (Terminated, December 31, 2022); Chemocentryx: Consultant (Terminated, December 31, 2022); Chugai: Consultant (Terminated, December 31, 2022); GSK: Consultant (Terminated, December 31, 2022); Horizon Therapeutics: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); InflaRx: Consultant (Terminated, December 31, 2022); IQVIA: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Kyverna: Consultant (Terminated, December 31, 2022); Mirabio: Consultant (Terminated, December 31, 2022); NIH: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); PPD: Consultant (Ongoing); Prometheus: Consultant (Ongoing); Q32: Consultant (Ongoing); Regeneron: Consultant (Terminated, December 31, 2022); Roche-Genentech: Consultant (Ongoing); Roivant: Consultant (Terminated, December 31, 2022); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); Spruce Biosciences: Consultant (Terminated, December 31, 2022); Star Therapeutics: Consultant (Ongoing); Steritas: Chair, Scientific Advisory Board (no fiduciary responsibilities) (Ongoing); ZenasBio: Consultant (Ongoing)
Meet the Professor: IgG4-Related Disease
Monday, November 18, 2024
7:30 AM – 8:30 AM Eastern Time
Disclosure(s): Abvie: Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Argenx: Consultant (Ongoing); Aztrazeneca: Consultant (Terminated, December 31, 2022); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Celgene: Consultant (Terminated, December 31, 2022); Chemocentryx: Consultant (Terminated, December 31, 2022); Chugai: Consultant (Terminated, December 31, 2022); GSK: Consultant (Terminated, December 31, 2022); Horizon Therapeutics: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); InflaRx: Consultant (Terminated, December 31, 2022); IQVIA: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Kyverna: Consultant (Terminated, December 31, 2022); Mirabio: Consultant (Terminated, December 31, 2022); NIH: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); PPD: Consultant (Ongoing); Prometheus: Consultant (Ongoing); Q32: Consultant (Ongoing); Regeneron: Consultant (Terminated, December 31, 2022); Roche-Genentech: Consultant (Ongoing); Roivant: Consultant (Terminated, December 31, 2022); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); Spruce Biosciences: Consultant (Terminated, December 31, 2022); Star Therapeutics: Consultant (Ongoing); Steritas: Chair, Scientific Advisory Board (no fiduciary responsibilities) (Ongoing); ZenasBio: Consultant (Ongoing)
Meet the Professor: IgG4-Related Disease
Monday, November 18, 2024
11:30 AM – 12:30 PM Eastern Time
Disclosure(s): Abvie: Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Argenx: Consultant (Ongoing); Aztrazeneca: Consultant (Terminated, December 31, 2022); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Celgene: Consultant (Terminated, December 31, 2022); Chemocentryx: Consultant (Terminated, December 31, 2022); Chugai: Consultant (Terminated, December 31, 2022); GSK: Consultant (Terminated, December 31, 2022); Horizon Therapeutics: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); InflaRx: Consultant (Terminated, December 31, 2022); IQVIA: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Kyverna: Consultant (Terminated, December 31, 2022); Mirabio: Consultant (Terminated, December 31, 2022); NIH: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); PPD: Consultant (Ongoing); Prometheus: Consultant (Ongoing); Q32: Consultant (Ongoing); Regeneron: Consultant (Terminated, December 31, 2022); Roche-Genentech: Consultant (Ongoing); Roivant: Consultant (Terminated, December 31, 2022); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); Spruce Biosciences: Consultant (Terminated, December 31, 2022); Star Therapeutics: Consultant (Ongoing); Steritas: Chair, Scientific Advisory Board (no fiduciary responsibilities) (Ongoing); ZenasBio: Consultant (Ongoing)
Monday, November 18, 2024
5:45 PM – 7:45 PM Eastern Time
No financial relationships with ineligible companies to disclose